Chemotherapy-induced Nausea And Vomiting (CINV)
Palonosetron effectively prevents and manages delayed CINV in patients with non-Hodgkin lymphoma.
The American Society of Clinical Oncology (ASCO) convened a panel of experts to update its clinical guidelines for antiemetic therapy in patients receiving chemotherapy. A notable change is the addition of olanzapine in emetic regimens for adult patients.
Long-acting NK-1 receptor antagonist rolapitant demonstrates significant efficacy in managing CINV in patients receiving HEC or MEC for cancer.
Supplemental ginger before and during treatment raises antioxidant levels in patients undergoing chemotherapy.
This study compared the effectiveness of olazapine, palonosetron, and ondansetron in the treatment of CINV in patients receiving HSCT who are refractory to prophylactic antiemetic agents.
Antiemetic overuse is prevalent among patients with cancer receiving emetogenic chemotherapy and leads to unnecessary spending.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone significantly improved the prevention of CINV in patients with GI and CRC cancers receiving highly or moderately emetogenic chemotherapy.
The Multinational Association of Supportive Care in Cancer and the European Society for Medical Oncology updated their 2009 consensus recommendations for the prevention of acute CINV in pediatric patients with cancer.
Some of our patients receive olanzapine (Zyprexa) as an antiemetic. Is this a typical use of this drug?
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|